Avis Budget Group, Inc. (CAR)
Analysts Estimate Avis Budget Group (CAR) to Report a Decline in Earnings: What to Look Out for
Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAR Group Limited (CSXXY) Q2 2026 Earnings Call Transcript
CAR Group Limited (CSXXY) Q2 2026 Earnings Call Transcript
Reasons Why You Should Retain Avis Budget Stock in Your Portfolio
CAR's rental-led growth shines as Q4 2025 revenues and earnings are set to rise, backed by fleet efficiency, tech upgrades and the premium Avis First launch.
Why Is Avis Budget (CAR) Down 8% Since Last Earnings Report?
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
Avis Budget Stock Declines 11% Despite Reporting Q3 Earnings Beat
CAR's third-quarter 2025 earnings and revenues top estimates, yet the stock slides 11% as investors react to mixed segmental results.
CAR Group Limited (CSXXY) Shareholder/Analyst Call Transcript
CAR Group Limited (OTCPK:CSXXY) Shareholder/Analyst Call October 30, 2025 8:01 PM EDT Company Participants Patrick Redmond O'Sullivan William Elliot - MD, CEO & Director Nicole Birman - General Counsel & Company Secretary David Wiadrowski Edwina Gilbert Conference Call Participants Henry Stephens Conversation Patrick Redmond O'Sullivan Good morning, all, and welcome to the 2025 Annual General Meeting of CAR Group Limited. My name is Pat O'Sullivan, and I'm Chair of the company and Chair of this meeting.
Ethic Inc. Acquires New Position in Avis Budget Group, Inc. $CAR
Ethic Inc. acquired a new stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,894 shares of the business services provider's stock, valued at approximately $330,000. Several other
Hemogenyx shares rise after safety board backs next trial phase for CAR-T therapy
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares climbed as much as 8% in early trading after the biotech company said US regulators had cleared its experimental CAR-T therapy for leukaemia to move to a higher dose level in its ongoing Phase I trial. The independent Data Safety Monitoring Board, which oversees the study, reviewed safety data from the first three adult patients treated with Hemogenyx's HG-CT-1 therapy for relapsed or refractory acute myeloid leukaemia and found no dose-limiting toxicities.
Avis Budget Group (CAR) Q3 Earnings and Revenues Top Estimates
Avis Budget Group (CAR) came out with quarterly earnings of $10.11 per share, beating the Zacks Consensus Estimate of $8.11 per share. This compares to earnings of $6.65 per share a year ago.
Avis Budget Group Up 4% After Q3 Earnings: Here's Why
Avis Budget Group (NASDAQ: CAR) delivered a sharp earnings surprise on Monday after the close, posting $10.11 in adjusted EPS that crushed consensus expectations of $8.12.
Hemogenyx rises on progress in CAR-T trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed or refractory acute myeloid leukaemia (AML). The London-listed company said its third patient had been treated successfully, with the therapy meeting initial safety targets and showing signs of efficacy.
Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss
CAR plunges 22% after second-quarter 2025 earnings and revenues miss estimates despite a nearly 98% YTD surge in shares.
